HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SKLB1206

a multikinase inhibitor that also targets erbB2 and erbB4; an antineoplastic agent; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - SKLB1206: 1

Experts

1.	Cao, Zhixing: 1 article (04/2012)
2.	Chen, Xin: 1 article (04/2012)
3.	Feng, Shan: 1 article (04/2012)
4.	Ji, Pan: 1 article (04/2012)
5.	Liu, Jingjing: 1 article (04/2012)
6.	Luo, Shidong: 1 article (04/2012)
7.	Pan, Youli: 1 article (04/2012)
8.	Wang, Bing-Lin: 1 article (04/2012)
9.	Wang, Lijiao: 1 article (04/2012)
10.	Wang, Xiaoyan: 1 article (04/2012)

Related Diseases

1.

Neoplasms (Cancer)

04/01/2012 - "Collectively, these preclinical evaluations may support clinical development of SKLB1206 for cancers with EGFR-activating/resistance mutations or EGFR/ErbB2 overexpressed."
04/01/2012 - "In vivo, oral administration of SKLB1206 showed complete tumor regression in gefitinib-sensitive HCC827 and PC-9 xenograft models and showed a considerable antitumor effect on the gefitinib-resistant H1975 model as well as other EGFR/ErbB2-overexpressing or -dependent tumor models including A431, LoVo, and N87 established in athymic mice. "
04/01/2012 - "SKLB1206 also showed a potent antiangiogenesis effect in vitro, in a zebrafish embryonic angiogenesis assay, and in an alginate-encapsulate tumor cell assay. "

Related Drugs and Biologics

1.	Angiogenesis Inhibitors
2.	Alginates
3.	Gefitinib (Iressa)

Related Therapies and Procedures

1.	Oral Administration